AIM ImmunoTech opens enrollment in Phase 1b/2 trial of Ampligen + Imfinzi for pancreatic cancer

AIM ImmunoTech Inc.

Enrollment open at Erasmus MC for DURIPANC study combining Ampligen + AstraZeneca's Imfinzi; dosing expected soon.
Phase 1b portion will enroll up to 18 subjects; Phase 2 up to 25 patients with metastatic pancreatic ductal adenocarcinoma.
Ampligen dose escalation from 200 mg to 400 mg IV twice weekly; durvalumab 1500 mg IV every 4 weeks for up to 48 weeks.
Primary objectives: safety in Phase 1b, clinical benefit rate in Phase 2.
AIM recently received a U.S. patent for using Ampligen in combination with an anti-PD-L1 antibody.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.